|
 |
European BioPharmaceutical Review
|
| In the search to understand, prevent and treat disease, clinical trials involving healthy volunteers and patients play an essential role. How and why such trials are conducted needs to be understood by the public - as well as by key decision-makers - so that clinical research in the UK receives the focus and attention necessary for it to be successful. Nearly a quarter of the world's top 100 medicines were developed in the UK, making it a leading centre for clinical trials. But clinical studies are increasingly conducted around the world so that greater numbers of patients and different ethnicities can be included in a study. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Professor Trevor Jones, Director General at ABPI
Professor Trevor Jones is Director General of The Association of the British Pharmaceutical Industry, directing all activities relating to the UK pharmaceutical industry, including government relations, on behalf of 80 national and international pharmaceutical companies. From 1987 to 1994, Professor Jones was a main Board Director of Wellcome plc, the UK-based pharmaceuticals company, where he was responsible for R&D, including the development of Zovirax, AZT, Malarone, Lamictal and Tracrium. He was awarded the CBE in the 2003 New Year's Honours List.
|
|
|
|
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Ultra slim and ultra quick
More info >>
|
|
 |
